RecruitingInterventional

Single Center Observational Study Using Spinal Laser Interstitial Thermal Therapy (sLITT) in the Treatment of Spine Metastases and Tumors

NCT ID: NCT06548061Sponsor: Dartmouth-Hitchcock Medical CenterLast updated: 2026-02-06

Summary

The objective of this clinical study is to evaluate the efficacy and safety of spinal laser interstitial therapy in the treatment of metastatic spinal tumors. The investigators hypothesize that rates of local tumor control are comparable between conventional open surgical techniques and spinal laser interstitial therapy.

Arms & interventions

DeviceClearPoint Prism
Spine laser interstitial therapy used instead of open decompression followed by spine stereotactic radiosurgery (SSRS).

Outcome measures

Primary

Local tumor control
Any increase in the epidural spinal cord compression score (ESCC grade 1 (no compression) to 3 (spinal cord compression) compared to the initial post-procedure MRI will be considered local radiographic failure or evidence of tumor recurrence.
Time frame: Local control rate at 12 months

Secondary

Evaluate neurologic function before and after sLITT.
Time frame: 3, 6, 9, and 12 months post-operatively

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: 1. Histology confirmed spinal tumor involving the T2-T12 spine segments. 2. Indication for spine stereotactic radiosurgery or palliative intervention. 3. Normal neurologic exam at the time of presentation (Frankel grade E). Exclusion Criteria: 1. Contraindication to MRI 2. ANY neurologic deficit 3. Tumor spanning more than 3 consecutive vertebral segments 4. Contraindication to general anesthesia 5. Pregnancy

Study locations (1)

Dartmouth Health

Lebanon, New Hampshire, 03766

Recruiting

Lauren Sinks, MPH · Contact

(603) 653-9021 lauren.j.sinks@hitchcock.org